Scarica l'app Stockscreener
0.4875
3.22%
-0.0162
Precedente Chiudi:
$0.5037
Aprire:
$0.4804
Volume 24 ore:
2.05M
Relative Volume:
0.63
Capitalizzazione di mercato:
$10.85M
Reddito:
-
Utile/perdita netta:
$-16.51M
Rapporto P/E:
-0.3604
EPS:
-1.3528
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
-64.67%
1M Prestazione:
-48.68%
6M Prestazione:
-78.33%
1 anno Prestazione:
-81.32%
Intervallo 1D:
$0.4521
$0.4959
Intervallo di 1 settimana:
$0.37
$1.14
Portata 52W:
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Nome
Medicus Pharma Ltd
Settore
Industria
Telefono
610-540-7515
Indirizzo
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4851 | 11.26M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
992.89 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.87 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
226.00 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.48 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.96 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Medicus Pharma on Bloomberg World - The Arizona Republic
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy - MyChesCo
Medicus Pharma to spotlight AI-driven drug development at Longwood Miami CEO Forum - Proactive financial news
Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum - TipRanks
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum - Eagle-Tribune
Medicus Pharma to Present Drug Development Programs at Roth Conference - MyChesCo
MDCX Maintains Buy Rating with Stable Price Target | MDCX Stock News - GuruFocus
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive financial news
Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma - TipRanks
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer - Proactive financial news
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset - The Manila Times
SkinJect cancer patch clears 3 in 4 lesions in trial, may spare surgery - Stock Titan
Aug Ideas: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Medicus Pharma CEO discusses Phase 2 skin cancer resultsICYMI - Proactive financial news
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture - TipRanks
Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch - MyChesCo
Aug Intraday: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestWeekly Profit Recap & Low Drawdown Trading Techniques - baoquankhu1.vn
Small caps: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive financial news
Small cap wrap: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive Investors
Medicus Pharma Ltd Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance And 40% Histological Clearance (CR) At Day 57 In 200µg Cohort - marketscreener.com
Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment - Proactive financial news
MDCX Navigates Uncertain Waters Amid Recent Earnings and Market Trends - timothysykes.com
Medicus Pharma Stock Swings After Skin Cancer Treatment Results - Benzinga
Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma - Yahoo Finance
Medicus Pharma Posts Strong Phase 2 Data for Microneedle Basal Cell Carcinoma Therapy - TipRanks
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort - Bitget
Microneedle skin cancer patch shows 73% clearance in Medicus trial - Stock Titan
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM - ACCESS Newswire
MDCXMedicus Pharma on Bloomberg World - Revista ADVFN
Medicus Pharma Showcases SkinJect and Teverelix Strategy at Roth Conference - TipRanks
Medicus Pharma to present at Roth Conference - Proactive financial news
Medicus Pharma To Participate in the 38th Annual Roth Conference - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Treasure Coast News
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Ashland Times-Gazette
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Daily Comet
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Montgomery Advertiser
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
MDCX Technical Analysis & Stock Price Forecast - Intellectia AI
Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):